Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN1673386 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Cytochrome P450, Family 1, Subfamily A, Polypeptide 2 (CYP1A2) (Middle Region) antibody
- Antibody type
- Polyclonal
- Antigen
- A synthetic peptide corresponding to a sequence in the middle region of human CYP1A2, different from the related rat and mouse sequences by three amino acids.Immunogen affinity purified.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Epitope
- Middle Region
- Isotype
- IgG
- Vial size
- 100 μg
- Storage
- At -20°C for one year. After reconstitution, at 4°C for one month. It can also be aliquotted and stored frozen at -20°C for a longer time.
- Handling
- Avoid repeated freezing and thawing.
Submitted references CYP1A2 is more variable than previously thought: a genomic biography of the gene behind the human drug-metabolizing enzyme.
Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans.
Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression.
Browning SL, Tarekegn A, Bekele E, Bradman N, Thomas MG
Pharmacogenetics and genomics 2010 Nov;20(11):647-64
Pharmacogenetics and genomics 2010 Nov;20(11):647-64
Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans.
Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T
Journal of biochemistry 1999 Apr;125(4):803-8
Journal of biochemistry 1999 Apr;125(4):803-8
Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression.
Ikeya K, Jaiswal AK, Owens RA, Jones JE, Nebert DW, Kimura S
Molecular endocrinology (Baltimore, Md.) 1989 Sep;3(9):1399-408
Molecular endocrinology (Baltimore, Md.) 1989 Sep;3(9):1399-408
No comments: Submit comment
No validations: Submit validation data